Looking at 2005 to 2010, our approach to – and investments in – the Chinese market created significant value for the Chinese society and Novo Nordisk. Today, China is the third biggest market in Novo Nordisk’s business and the second largest insulin market. In 2010, we realised a 63% market share and sales of DKK 4,500 million, and insulin sales by volume of 12,000 mega units. Our long-term commitment to changing diabetes in China has built trust and our reputation among physicians while strengthening the relationship with key government agencies. Our goal is to be perceived as the world’s leading diabetes are company, leading the fight against diabetes type 1 and type 2. The trendline has been positive and stable compared to competition, and increasing among diabetes specialists.